// App-Quantinova.ai

4023 : Janus Kinase Inhibition By Ruxolitinib Combined with Nilotinib Has Superior Anti-Leukemia Propagating Cells Effect in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Yuan Kong

Principal Investigators

  • Yi-Lin Wu

  • Yang Song

  • Min-Min Shi

  • Ya-Zhen Qin

  • Yue-Yun Lai

  • Hao Jiang

  • Qian Jiang

Medical Centers

  • Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China

  • Institute of Hematology, Peking University Peoples Hospital, Beijing,

  • Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

  • Peking University People's Hospital, Beijing, China

  • Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

  • Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Philadelphia chromosome–positive (Ph+) ALL

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Cluster of Differentiation 34

  • IL-2 receptor β

Drug/Treatment

  • Ruxolitinib phosphate

  • Nilotinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved